The number of prescriptions written for MannKind's inhaled insulin drug Afrezza are barely making a dent in the diabetes market five months after partner Sanofi launched the product. The number of ...
Millions of people around the world live with diabetes mellitus. Many of them have medication and specific dietary management ...
Inhaled insulin is now considered “standard of care” for diabetics, according to updated guidelines from the American Diabetes Association. Inhaled insulin works faster than injections or pumps, ...
MannKind (MNKD) surged to a 52-week high of $11.11 on Thursday on high volume as the impending July 15 date for FDA approval of the company's inhaled insulin drug Afrezza approaches. MannKind ...
known as the Technosphere insulin-inhalation system (Afrezza). It starts to work within 10-15 minutes, has a peak time of 30 minutes, and lasts about 3 hours. Like the injectable version ...
He's majoring in aerospace engineering. He said that while on campus, his Afrezza inhalation powder is perfect. "You can fit it in your pocket and carry it around,” Jones said. But, he said he ...
More information on the INHALE-3 study is available at: ClinicalTrials.gov(NCT05904743). Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic ...
While Afrezza faces challenges like pricing and reimbursement, MNKD's efforts to improve market penetration suggest a proactive strategy to turn around this underperforming asset. Market sentiment ...
Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is ...
Ofek, Elie, and Amanda Dai. "MannKind Corporation: Take a Deep Breath, This Time Afrezza Will Work." Harvard Business School Case 518-031, August 2017. (Revised July 2018.) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback